Article Text

Download PDFPDF

P2 Difficulties in managing a patient with multi-organ damage in systemic lupus erythematosus and a high risk of thrombotic events in antiphospholipid syndrome (case report)
  1. Fariza Cheldieva1,2,
  2. Tatiana Reshetnyak1,2,
  3. Anastasiia Shumilova1,
  4. Natalia Seredavkina1,
  5. Maria Cherkasova1,
  6. Tatiana Lisitsyna1,
  7. Anastasia Borisova3 and
  8. Alexander Lila1,2
  1. 1Federal State Budgetary Scientific Institution ‘Research Institute of Rheumatology named after V.A.Nasonova’, Moscow
  2. 2Federal State Budgetary Educational Institution of Further Professional Education ‘Russian Medical Academy of Continuous Professional Education’ of the Ministry of Healthcare of the Russian Federation, Rheumatology Academic Dept., Moscow
  3. 3Moscow Research Institute of Psychiatry, Serbsky NMRC PN MoH, Moscow, Russian Federation


Background Systemic lupus erythematosus (SLE) is a multisystem disease with many clinical manifestations. Late diagnosis, kidney damage, neuropsychiatric disorders, high risk of thrombotic events, resistance to therapy worsen the prognosis of the disease and increase mortality.

Methods Description of a clinical case of multiple organ damages in a patient with SLE and concomitant antiphospholipid syndrome (APS).

Results We describe a case report of organ damage in a patient with SLE and concomitant APS. The clinical and laboratory manifestations for the entire period of the disease are given below (table 1). Now the main manifestation of the disease in clinical finding are: active lupus nephritis of a kidney, relapse of venous thrombosis as a result of APS, thrombotic microangioencephalopathy, cognitive impairment and somatogenic astheno-depressive syndrome.

Abstract P2 Table 1

The clinical and laboratory manifestations for the entire period of the disease

Conclusions This clinical case demonstrates a patient with SLE presented in clinical features thrombosis, lupus glomerulonephritis class IV, AI 8, CI 2, high immunological disorders and concomitant APS. The difficulty in treating the patient is the consistently high immunological activity of the disease, the resistance of the therapy cytostatic and glucocorticoids, the inefficiency and intolerance of a number of oral anticoagulants: dabigatran etexilate and rivaroxaban — relapses of thrombosis, warfarin — the inability to reach the target levels of the international normalized ratio (INR) due to recurrent nosebleeds.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.